ALLERGAN HYPOTENSIVE LIPID PHASE III TRIALS FOR GLAUCOMA SET FOR EARLY 1998; BOTOX 1996 SALES UP 37% TO $67.2 MIL., WHILE DOMESTIC EYE CARE Rx SALES DROP
Allergan hopes to move one of its hypotensive lipid compounds into Phase III trials for treatment of intraocular pressure associated with glaucoma in early 1998, the company announced April 8.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth